ICER revising value assessment framework

The Institute for Clinical and Economic Review proposed revisions to the framework and methods it uses to guide its evidence reports, based on input from stakeholders. The organization will accept comments on the new value assessment framework until April 3, and intends to post a final description of updates by April 15.

The group proposed widening the range of incremental cost-effectiveness ratios used to assess the long term value of different treatments. It would include a ratio of $50,000 per additional quality-adjusted life year (QALY) at the lower bound, down from $100,000 per QALY. The upper bound would remain at $150,000 per QALY. The organization would also use estimated net prices, rather than wholesale acquisition costs (WACs), in its assessments...